<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653445</url>
  </required_header>
  <id_info>
    <org_study_id>D3569C00006</org_study_id>
    <nct_id>NCT00653445</nct_id>
  </id_info>
  <brief_title>Compare the Safety &amp; Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg</brief_title>
  <acronym>EXPLORER</acronym>
  <official_title>A 6wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel Group Study to Compare the Safety &amp; Efficacy of Rosuvastatin 40mg in Comb.With Ezetimibe 10mg in Subjects With Hypercholesterolaemia &amp; CHD or Atherosclerosis or a CHD Risk Equiv. (10 yr Risk Score &gt;20%).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare 6 weeks of treatment with rosuvastatin alone compared
      with 6 weeks of treatment of rosuvastatin combined with ezetimibe in achieving low density
      lipoprotein level goals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of rosuvastatin alone with rosuvastatin combined with ezetimibe by measuring fasting low-density lipoprotein cholesterol (LDL-C) levels at baseline and Week 6</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of rosuvastatin alone with rosuvastatin combined with ezetimibe by measuring fasting blood lipid levels levels at baseline and Week 6</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: by measuring adverse events &amp; abnormal laboratory markers to compare safety &amp; tolerability of rosuvastatin alone with rosuvastatin combined with ezetimibe</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 40mg/Ezetimibe 10mg combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>40mg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>10mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of CHD or clinical evidence of atherosclerosis or multiple risk factors that
             confer a high risk as defined in the protocol.

          -  Fasting LDL-C concentrations at Visit 1 as defined in the protocol.

          -  Discontinuation of all lipid lowering therapy at Visit 1.

        Exclusion Criteria:

          -  History of statin induced serious side effects, or serious hypersensitivity reaction
             to other statins.

          -  Subjects considered to be unstable by the investigator after the following events: a
             myocardial infarction (heart attack), unstable angina, myocardial revascularisation or
             another revascularisation procedure or a transient ischaemic attack (TIA) or stroke.

          -  Severe congestive cardiac failure (as defined by the protocol - Appendix I).

          -  Subjects awaiting a planned myocardial revascularisation prior to starting the study
             (i.e. planned prior to visit 1)..
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Ballantyne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for prevention of cardiovascular disease, Texas, USA</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>March 25, 2009</last_update_submitted>
  <last_update_submitted_qc>March 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Elisabeth Bj√∂rk</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Low density lipoproteins</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Crestor</keyword>
  <keyword>Ezetimibe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

